Home » Archive by Category


Shipping/Lab Services Assistant

May 6, 2016 – 9:08 am

Job Summary:
Performs general lab service functions such as solvent stocking, delivery & transport of lab supplies, glass wash service, package & compound delivery. In addition, providing shipping & receiving support: process, sort, and deliver pack […]

Social Media Sales and Marketing – $45,000-$100,000 (San Diego)

May 6, 2016 – 8:27 am

Online Marketing Agency Seeks 10 New Sales Agents
Motivated College Grads Welcome
We are open to hiring recent college grads with a strong desire to learn sales and marketing techniques and who are ready to work hard to achieve the next level in th […

MIODx Announces Close of Series Seed Funding

May 6, 2016 – 5:45 am

SAN FRANCISCO, May 6, 2016 /PRNewswire/ — MIODx, a pioneer in biomarker discovery, announced today the close of the $1.5 million dollar seed round.  “We’re very excited to have completed our seed round and execute on the company’s strategic plan,” said Sean Givens, the company’s COO and co-founder.  “This tranche of funding will allow MIODx to complete the clinical utility study for our VerifyDx Prostate Cancer test and begin commercialization of this much needed test,” he added. 

VerifyDx is an oncology testing platform that utilizes a highly multiplexed assay to interrogate expression levels of biomarkers implicated in cancer aggressiveness.  “Unlike tests today that only interrogate biomarkers in a single genomic pathway such as oncogene or methylation only, the VerifyDx test looks at biomarkers across four different genomic pathways and then applies a proprietary algorithm that provides better insight into the aggressiveness of a patient’s tumor,” explained Allen Northrup MIODx’s CEO.  “We started with prostate cancer because the current state of testing is not adequate for properly identifying which patients should undergo a radical prostatectomy from those that should be on watchful waiting,” he added.  The company plans to launch additional VerifyDx tests including colon, lung, and kidney following the commercialization of the prostate test.

MIODx is also developing, and has IP surrounding, the sequencing of T cell repertoires.  The company has stated that the first application of the TCR sequencing will be in immuno-oncology.  “Harnessing the immune system to fight cancer has been a complete game changer in the fight against cancer, but not everyone responds and many suffer immune related responses to the therapy.  Our test will help doctors identify patients that will respond to a certain therapy and which ones might suffer and adverse event,” Northrup stated.  The company is already in early discussions about using the test as a companion diagnostic for immuno-oncology therapies.

MIODx also announced today that they have entered into a lease for 3,000 sqft at the San Jose BioCube.  “We are happy to be part of the family of companies that call or have called the San Jose BioCube home.  With a history of successful companies such as Ariosa Diagnostics, Geneweave and Genia, we hope to continue the record of success,” Givens stated.

About MIODx

MIODx are pioneers in the discovery of early detection and prognostic cancer biomarkers through the company’s proprietary platforms.  The company’s VerifyDx™ platform utilizes a multiplex PCR assay and advanced bioinformatics to interrogate multiple DNA and RNA pathways that are implicated in highly metastatic cancer.  In addition to the VerifyDx™ platform, MIODx utilizes high throughput immunosequencing to generate information on T and B cell diversity that can be applied to monitoring a patient’s response to immunotherapy, discover new targets for drug companies, or as a way to profile an individual’s adaptive immune system over time.

Logo – http://photos.prnewswire.com/prnh/20160505/364288LOGO



West Coast Biotech Roundup: Acadia, Medivation, Verily, and More

May 6, 2016 – 5:40 am

Just a few weeks ago, the Silicon Valley tech entrepreneur and philanthropist Sean Parker committed $250 million of his Napster and Facebook fortune to a massive effort to accelerate ways to boost…

[[Click headline to continue reading.]]

Neurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data to be Presented at the American Psychiatric Association’s 2016 Annual Meeting in Atlanta

May 6, 2016 – 5:30 am

Four Abstracts Submitted and Accepted for the May 2016 APA Annual Meeting

SAN DIEGO, May 6, 2016 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia clinical trials of valbenazine will be presented at the American Psychiatric Association Annual Meeting in May. The four posters will include an evaluation of the impact of valbenazine on the psychiatric stability of subjects with underlying schizophrenia, schizoaffective disorder or mood disorder (including bipolar disorder or major depressive disorder), data assessing the effect of valbenazine stratified by baseline tardive dyskinesia severity, and an evaluation of valbenazine with concomitant antipsychotic use. The APA Annual Meeting is the largest international conference of psychiatrists and behavioral health specialists, bringing together an estimated 13,000 clinicians and scientists to address current topics in psychiatry.

Valbenazine data will be presented at the APA Annual Meeting poster sessions at the following dates and times:

Monday May 16th2pm-4pm

  • Tardive Dyskinesia and Valbenazine (NBI-98854) Response as a Function of Concomitant Antipsychotic Use

Tuesday May 17th2pm-4pm

  • Valbenazine (NBI-98854) is Effective for Treating Tardive Dyskinesia in Individuals with Schizophrenia or Mood Disorder
  • KINECT 3: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia
  • Psychiatric Stability Maintained in Tardive Dyskinesia Subjects Treated with Valbenazine (NBI-98854)

“We are very pleased to have four abstracts accepted for presentation at the American Psychiatric Association Annual Meeting in Atlanta in May. This meeting, coupled with our American Academy of Neurology presentations in April, demonstrates to health care providers the breadth and depth of our tardive dyskinesia clinical data across multiple treatment paradigms,” said Chris O’Brien, M.D., Chief Medical Officer at Neurocrine. “We have submitted seven abstracts between the American Academy of Neurology and the American Psychiatric Association Annual Meetings and all seven have been accepted; evidence of the consistency, quality and strength of the data emerging from our clinical program.”

About Valbenazine

VMAT2 is a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines (dopamine, norepinephrine, serotonin, and histamine) in pre-synaptic neurons. Valbenazine (NBI-98854), developed in the Neurocrine laboratories, is a novel, highly-selective VMAT2 inhibitor that modulates dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines, thereby reducing the likelihood of “off-target” side effects. Valbenazine is designed to provide low, sustained, plasma and brain concentrations of active drug to minimize side effects associated with excessive monoamine depletion.

Modulation of neuronal dopamine levels in diseases such as tardive dyskinesia, Tourette syndrome, Huntington’s chorea, schizophrenia, and tardive dystonia, which are characterized, in part, by a hyperdopaminergic state, may provide symptomatic benefits for patients with these diseases.

Neurocrine has received Breakthrough Therapy Designation from the FDA for valbenazine in the treatment of tardive dyskinesia and expects to file a New Drug Application for tardive dyskinesia in 2016. Valbenazine is also currently in Phase II development for Tourette syndrome.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc., and valbenazine, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. 

Neurocrine Biosciences, Inc. news releases are available through the Company’s website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine’s business and finances in general, as well as risks and uncertainties associated with NBI-98854 (valbenazine) development. Specifically, the risks and uncertainties the Company faces include risks that valbenazine development activities may not be completed on time or at all; risks that valbenazine development activities may be delayed for regulatory or other reasons, may fail to demonstrate that valbenazine is safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that valbenazine regulatory submissions may not occur or be submitted in a timely manner; risks that  valbenazine may not obtain regulatory approval or that the U.S. Food and Drug Administration or regulatory authorities outside the U.S. may make adverse decisions regarding valbenazine; risks that valbenazine may be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with the Company’s dependence on third parties for development and manufacturing activities related to valbenazine; risks that the Company will be unable to raise additional funding, if required, to complete development of valbenazine; risks and uncertainties relating to competitive products and technological changes that may limit demand for valbenazine; and other risks described in the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2016. Neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof.




SOURCE Neurocrine Biosciences, Inc.

Innovation in Laser Fibers:  Dornier MedTech HeatFlex(TM)

May 6, 2016 – 5:00 am

Powering Highest Sterilization & System Performance

ATLANTA, May 6, 2016 /PRNewswire/ — Dornier MedTech is a global medical device company known for its pioneering technologies and revolutionary therapies in urology.  Dornier will be showcasing their newest holmium laser fiber, Dornier HeatFlex™, at the 2016 American Urological Association’s Annual Meeting (AUA) in San Diego, California.

As the name suggests, this fiber is enhanced with special heat-resistance technology enabling it to withstand the extreme temperatures and conditions associated with anti-prion sterilization processes. In addition, given its durable construction, the HeatFlex™ fiber also features a unique optical and mechanical connection capability when utilizing Dornier’s Medilas H Solvo and UroPulse Laser Systems.  These paired features make HeatFlex™ one of the most versatile and state-of-the-art fibers on the market today.

Working efficiently, while preventing the transmission of diseases through medical equipment, is critical.  The combined heat-resistant and optimized-connection capability of this new fiber makes HeatFlex an ideal product for urologists looking for the highest levels of performance during kidney stone treatments,” said Mary Butler, Chief Technology Officer and VP of Product Marketing for Dornier MedTech.

The fight against transmissible diseases, nosocomial infections, and prion disease is one the highest public health priorities today. Steam sterilization at a temperature of 134C for 18 minutes has been recommended by International health Authorities to provide better assurance of preventing prion disease.  HeatFlex™ fibers are designed to tolerate these levels without compromising kidney stone treatment performance.  HeatFlex also represents the latest in a wave of market innovations Dornier MedTech has been making as part of their commitment to leading technology and improving life.

For additional information about Dornier MedTech’s HeatFlex™ fibers, please contact Valerie Schopmann at +1.770.514.6160 for an interview.

About Dornier MedTech – Dornier MedTech is a wholly-owned subsidiary of Accuron Medical Technology group (www.accuron.com) is a medical device company focused on providing leading technology and improving life by delivering scientifically superior products and solutions to physicians and patients involved in urological care.  As pioneers of the lithotripsy and a variety of surgical lasers, Dornier’s 40 years of innovation and service has made it one of the most trusted MedTech companies in the industry.  Dornier MedTech is headquartered in Munich, Germany with offices and distributors all over the world.  For more information, visit www.dornier.com.

About the Accuron Medical Technology Group – The Accuron Medical Technology Group is a privately owned by Temasek Holdings, through the business of Dornier MedTech GmbH, Veredus Laboratories and Advanced Materials Technologies Pte Ltd, provide therapeutic, diagnostic, and medical device manufacturing solutions to customers around the globe.  Veredus Laboratories Pte Ltd, specializes in the development, manufacture, and marketing of innovative molecular diagnostic solutions in the clinical, specialty, and custom testing markets based on a proprietary Lab-on-Chip platform.  Advanced Materials Technologies Pte Ltd serves the contract manufacturing needs of the medical technology sector through providing materials expertise and high precision engineering capabilities.

SOURCE Dornier MedTech

Mast Therapeutics Reports First Quarter 2016 Financial Results And Recent Highlights

May 6, 2016 – 5:00 am

– Completed enrollment in Phase 3 EPIC study of vepoloxamer in sickle cell disease- Announced positive top-line results from Phase 2a study of AIR001 in patients with heart failure with preserved ejection fraction (HFpEF)- AIR001 selected by Heart Failure Clinical Research Network (HFN) for multicenter, randomized, double-blind, placebo-controlled Phase 2 study in ~100 patients with HFpEF- Continued progress with ongoing Phase 2 study of vepoloxamer in chronic heart failure

SAN DIEGO, May 6, 2016 /PRNewswire/ — Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today reported financial results for the first quarter ended March 31, 2016.

“The first quarter of 2016 was a productive one for Mast.  Not only did we complete enrollment in our Phase 3 EPIC study of vepoloxamer in sickle cell disease, but also we announced positive data from a Phase 2a study of AIR001 in patients with heart failure with preserved ejection fraction conducted at Mayo Clinic, and the selection of AIR001 for a double-blind, placebo-controlled Phase 2 study in approximately 100 patients with HFpEF to be conducted at premier U.S. clinical centers that make up the HFN,” stated Brian M. Culley, Chief Executive Officer.

“With 388 patients, the EPIC study was the largest placebo-controlled study in sickle cell disease ever concluded and should provide many insights into the activity of vepoloxamer in this indication. Importantly, vepoloxamer has the potential to become the first and only approved therapy for shortening the duration of a sickle cell vaso-occlusive crisis and we are working diligently toward generating top-line results, which we expect to announce this quarter,” continued Mr. Culley.  “Meanwhile, we are advancing our two heart failure programs. Our 150-patient Phase 2 study of vepoloxamer in chronic heart failure is ongoing, with ten study sites now open, and the HFN’s 100-patient Phase 2 study of AIR001 in HFpEF is expected to begin in the third quarter of 2016.”

First Quarter 2016 Operating Results
The Company’s net loss for the first quarter of 2016 was $11.2 million, or $0.06 per share (basic and diluted), compared to a net loss of $9.6 million, or $0.06 per share (basic and diluted), for the same period in 2015.

Research and development expenses for the first quarter of 2016 were $7.9 million, an increase of $1.9 million, or 30%, compared to $6.0 million for the same period in 2015.  The increase was due mainly to increases of $0.9 million in external nonclinical study fees and expenses, $0.5 million in external clinical study fees and expenses, and $0.3 million in personnel expenses. 

The increase in external nonclinical study fees and expenses was due primarily to increased costs related to preparation for a new drug application for vepoloxamer ($0.5 million) and research-related manufacturing for vepoloxamer ($0.5 million), offset by a decrease in research-related manufacturing for AIR001 ($0.1 million).  The increase in external clinical study fees and expenses was due primarily to increased costs related to the Phase 2 study of vepoloxamer in heart failure ($0.5 million) and the EPIC study ($0.3 million), offset by a decrease related to discontinuation of a Phase 2 study of vepoloxamer in acute limb ischemia, which the Company began to wind-down in the third quarter of 2015 ($0.3 million). 

Selling, general and administrative (SG&A) expenses for the first quarter of 2016 were $2.8 million, a decrease of $0.8 million, or 21%, compared to $3.6 million for the same period in 2015. SG&A expenses for the first quarter of 2015 included $0.4 million of severance expenses and $0.3 million of share-based compensation resulting from the termination of employment of the Company’s former president and chief operating officer in February 2015 and the acceleration of stock option vesting pursuant to the terms of his option agreements.

Interest expense for the first quarter of 2016 was $0.5 million, which was related to the Company’s debt facility.  There was no interest expense for the first quarter of 2015.

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company is developing two clinical-stage investigational new drugs for serious or life-threatening diseases and conditions. Vepoloxamer, the Company’s lead product candidate, is in Phase 3 clinical development for the treatment of vaso-occlusive crisis in patients with sickle cell disease and in Phase 2 clinical development for the treatment of patients with heart failure.  Enrollment in the Company’s 388-patient Phase 3 study of vepoloxamer in patients with sickle cell disease, known as the EPIC study, was completed in February 2016.  Enrollment in the Company’s Phase 2 study of vepoloxamer in patients with chronic heart failure is ongoing.  AIR001, the Company’s second product candidate, is in Phase 2 clinical development for the treatment of patients with heart failure with preserved ejection fraction (HFpEF). Enrollment in a Phase 2a study of AIR001 in patients with HFpEF is ongoing and AIR001 was recently selected by the Heart Failure Clinical Research Network for evaluation in a 100-patient, multicenter, randomized, double-blind, placebo-controlled, Phase 2 study in patients with HFpEF.  More information can be found on the Company’s web site at www.masttherapeutics.com. (Twitter: @MastThera

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the Company’s current expectations and assumptions. Such forward-looking statements may be identified by the use of forward-looking words such as “expect,” “intend,” “plan,” “anticipate,” “believe,” among others, and include, but are not limited to, statements relating to prospects for successful development and commercialization of the Company’s product candidates, including vepoloxamer for the treatment of vaso-occlusive crisis of sickle cell disease, and anticipated timing of achievement of development milestones, such as commencement and completion of clinical studies and announcement of study data.  There are a number of factors that could cause or contribute to material differences between actual events or results and the expectations indicated by the forward-looking statements. These factors include, but are not limited to:  the inherent uncertainty of outcomes in ongoing and future studies of the Company’s product candidates and the risk that its product candidates may not demonstrate adequate safety, efficacy or tolerability in one or more such studies, including vepoloxamer in the Phase 3 “EPIC” study; risks associated with the Company’s ability to manage operating expenses and obtain additional capital as needed; the Company’s potential inability to continue as a going concern if it does not raise additional capital as needed; the risk that the Company may be required to repay its outstanding debt obligations on an accelerated basis and/or at a time that could be detrimental to its financial condition, operations and/or business strategy, including the prepayment of $10 million of the principal balance of its debt facility if results from the EPIC study are not positive; the potential for the Company to significantly delay, reduce or discontinue current and/or planned development and commercial-readiness activities or sell or license its assets at inopportune times if it is unable to raise sufficient additional capital as needed; delays in clinical study closeouts, including blinded data review and quality control and assurance procedures; the risk that, even if EPIC study results are positive, the FDA may require a second Phase 3 study or other clinical or nonclinical studies to demonstrate substantial evidence of vepoloxamer’s effectiveness for sickle cell patients or to provide additional safety and tolerability data or that the FDA may require changes to manufacturing controls or processes that could delay filing of a new drug application; delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a “clinical hold,” and/or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; the potential that, even if clinical studies of a product candidate in one indication are successful, clinical studies in another indication may not be successful; the Company’s dependence on third parties to assist with important aspects of development of its product candidates, including conduct of its clinical studies and supply and manufacture of clinical trial material, and, if approved, commercial product, and the risk that such third parties may fail to perform as expected, leading to delays in product candidate development or approval or inability to meet market demand for approved products, if any; the risk that, even if the Company successfully develops a product candidate in one or more indications, it may not realize commercial success and may never achieve profitability; the risk that the Company is not able to obtain and maintain effective patent coverage or other market exclusivity protections for its products, if approved, without infringing the proprietary rights of others; and other risks and uncertainties more fully described in the Company’s press releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law. 

[Tables to Follow]


Mast Therapeutics, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)

Three months ended

March 31,




Total net revenue

$                    —

$                    —

Operating expenses:

     Research and development



     Selling, general and administrative



     Depreciation and amortization



     Total operating expenses



Loss from operations



Interest income, interest expense and other income/(expense), net



Net loss

$           (11,207)

$              (9,616)

Net loss per share – basic and diluted

$              (0.06)

$              (0.06)

Weighted average shares – basic and diluted




Mast Therapeutics, Inc.
Balance Sheet Data
(In thousands)

March 31,


December 31,


Cash, cash equivalents and investment securities

$               37,089

$              40,981

Working capital



Total assets



Total liabilities



Stockholders’ equity




Logo – http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a


SOURCE Mast Therapeutics, Inc.

venBio Closes $315 Million Life Sciences Venture Capital Fund

May 6, 2016 – 4:30 am

SAN FRANCISCO, May 6, 2016 /PRNewswire/ — venBio Partners LLC, a global life sciences investment firm, today announced the closing of the venBio Global Strategic Fund II, its second life sciences venture capital fund, for a total of approximately $315 million, exceeding its target of $250 million. venBio’s Strategic Fund II is anchored by major investments from three strategic limited partners – Amgen, Merck, and Baxalta – along with a group of financial Limited Partners.

“We believe our fund model is unique. With the return of Amgen and Baxalta, along with the addition of Merck, the commitment from our Strategic Limited Partners is now larger than ever,” said Robert Adelman, M.D., managing partner at venBio. “Our investment model will remain the same. We continue to seek to finance promising life sciences companies that focus on therapeutics which we believe will make a difference for unmet medical needs.” 

“We tend to lead or co-lead our deals and take an active role in our investments. We often build management teams as well as syndicates,” commented Corey Goodman, Ph.D., managing partner at venBio. “Whether a company is viewed traditionally as early or late stage, we are interested in best-in-class therapeutics. Our goal is to have our capital carry the company to proof-of-concept clinical data.”

The venBio Strategic Fund II is led by Drs. Adelman and Goodman. New members joining the team to support Fund II are Aaron Royston, M.D., as principal, and Jaume Pons, Ph.D., as venture partner. In addition to the San Francisco team, venBio is also overseen by Behzad Aghazadeh, Ph.D., a managing partner in New York.

“For Fund II, we are delighted to have added Aaron Royston and Jaume Pons to our investment team,” commented Dr. Goodman.

Dr. Royston was previously a senior associate at Vivo Capital, and before that a biotech consultant at Bain. He received his M.D. from U. Penn., his B.S. from Duke, and coordinated clinical research at Mt. Sinai.

Dr. Pons is currently CEO of Alexo Therapeutics, a venBio portfolio immuno-oncology company. He was previously a senior vice president at Pfizer and chief scientific officer at Rinat, Pfizer’s immuno-oncology center. He specializes in protein engineering. Dr. Pons has brought 12 antibodies into the clinic, with three currently in Phase 3. He previously worked at Chiron and was a postdoctoral fellow at U.C. Berkeley.

The two venBio strategic funds have invested in 14 companies to date, including: Cytos (now KURN), Aragon (acquired by J&J), Solstice, Labrys (acquired by Teva), Seragon (acquired by Roche/Genentech), Aurinia (AUPH), Heart Metabolics, Metacrine, Alexo, Precision Biosciences, Checkmate, Adheren, Apellis, and Nabriva (NBRV). 

About venBio

venBio is a life sciences investment firm, partnering with industry leaders to build and invest in game-changing medicines and technologies with a focus on novel therapeutics for unmet medical needs. With a presence in San Francisco, CA and New York, NY, venBio manages both a long / short equity strategy along with venture capital funds which are backed by leading life sciences companies and qualified financial investors. See: www.venbio.com.

Media Contact:
Jason Spark
Canale Communications

Logo – http://photos.prnewswire.com/prnh/20160505/364451LOGO 


SOURCE venBio Partners

Senior Biostatistician or Biostatistician, Clinical Trials Pharmaceuticals – Pharma-Cruiting Life Sciences Executive Search – San Diego, CA

May 6, 2016 – 4:11 am

Pharma-Cruiting Life Sciences Executive Search is seeking a Biostatistician or Senior Biostatistician for our pharmaceutical company client . *Job summary*
From Indeed – 06 May 2016 11:11:05 GMT
– View all San Diego jobs

Graduating and want industry experience?!

May 5, 2016 – 5:14 pm

We are looking for candidates who have their BS in Chemistry, Biochemistry, Biology, Molecular Biology, Microbiology, Pharmacology, and other related fields.
We have entry level positions in the lab that will help build your resume.
We also have po […